API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ZEN-3694 (ZEN003694), orally bioavailable small molecule, in initro studies selectively binds to BET proteins with >20 fold selectivity over non-BET bromodomains inhibiting interaction of acetylated histone peptide with IC50 values in low nM range.
Lead Product(s): ZEN003694,Talazoparib
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Merck, Pfizer, UCSF and Newsoara join the list of collaborators involved in Zenith's development of ZEN-3694 in epigenetic combination therapy programs.
Lead Product(s): ZEN003694,Enzalutamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020